


Consensus Conference on Clinical Practice in Chronic GVHD Regensburg

6. - 7. November 2009



Hörsaal A2

University of Regensburg

Stem cell transplantation program

Organisation:

Prof. Dr. R. Andreesen, Prof. Dr. E. Holler, Dr. D. Wolff

Gefördert von:



Deutsche José Carreras Leukämie-Stiftung e.V.



Deutsche Arbeitsgemeinschaft für Knochenmark-
und Blutstammzelltransplantation (DAG-KBT e.V.)

Dear colleagues,

we are pleased to invite you to the Consensus conference on Clinical Practice in chronic GVHD 2009 held in Regensburg. Chronic GVHD continues to be a challenge in clinical practice balancing GVHD treatment against toxicity and infectious morbidity. Furthermore chronic GVHD remains the leading cause of long term morbidity and mortality after hematopoietic stem cell transplantation. Despite of its clinical importance, progress in understanding of pathophysiology and treatment has been rather slow. More recently chronic GVHD has moved into focus of transplant physicians starting with the NIH headed consensus conference on chronic GVHD. While this has led to considerable progress in the quality of clinical trials, the current challenge is to improve diagnosis, severity grading and treatment in clinical routine. The 2009 consensus conference is aiming to develop feasible standards for diagnosis and severity grading of chronic GVHD and to provide guidelines for immunosuppressive as well as supportive treatment of chronic GVHD.

H. Greinix (Wien)

A. Lawitschka (Wien)

H. Bertz (Freiburg)

R. Schwerdtfeger (Wiesbaden)

E. Holler and D. Wolff (Regensburg)

Friday, 6.11.2009

- 11.00 – 12.30 **Lunch**
- 12.30 – 13.00 **Opening**
(R. Andreesen, E. Holler, S. Pavletic)
- 13.00 – 15.30 **Joint Session**
Diagnosis and Staging of chronic GVHD
(Chair: H. Greinix, S. Pavletic)
- 15.30 – 16.00 **Coffee break**
- 16.00 – 18.30 **Meeting of the subcommittees**
First-Line treatment of chronic GVHD
(Chair: D. Wolff, G. Socie)
Second-Line treatment of chronic GVHD
(Chair: R. Schwerdtfeger, E. Holler, M. Mohty)
Supportive Therapy
(Chair: H. Bertz, S. Lee)

Welcome reception

Saturday 7.11.2009 **Presentation of the Consensus**

- 9.00 – 10:30 Diagnosis and Staging
(Chair: H. Greinix, S. Pavletic)
- 10.30 **Coffee break**
- 11.00 - 12.30 Supportive Therapy
(Chair: H. Bertz, S. Lee)
- 12.30 **Lunch**
- 13.00 - 14.00 First Line Treatment
(Chair: D. Wolff, G. Socie)
- 14.00 -15.30 Second Line Treatment
(Chair: R. Schwerdtfeger, E. Holler, M. Mohty)
- 15.30 Conclusion
(E. Holler, S. Pavletic)

Topics

1. First line treatment of chronic GVHD

Steroids

Calcineurin inhibitors

Mycophenolic acid

Topical treatment (PUVA, topical steroids, topical calcineurin-inhibitors etc.)

Antibodies (ATG, Campath, Etanercept etc.)

2. Second line treatment of chronic GVHD

Steroids

Calcineurin-inhibitors

mTor Inhibitors (Sirolimus and Everolimus)

Mycophenolic acid

Antibodies (ATG, Campath, Etanercept, Rituximab etc.)

Topical treatment

Photopheresis

Cytostatic treatment (Pentostatin, MTX, Cyclophosphamide)

Total nodal irradiation

Thalidomide

Hydroxychloroquin

Retinoids

Paediatric aspects

3. Supportive Therapy

Organ specific supportive therapy

Skin

Mouth and oral cavity

Eyes

Vagina

Lung

Neurologic system

Musculoskeletal system

Osteoporosis / Osteonecrosis

Immunology incl. vaccinations and infections

Psychosocial

Others: (thyroid gland, hormone replacement, rehabilitation, fertility, renal insufficiency, cardiac problems)

Paediatric aspects

4. Standards on diagnosis, grading and documentation of chronic GVHD

Diagnosis of chronic GVHD

Severity grading

Risk assessment

Documentation of the clinical course of chronic GVHD

Paediatric aspects

Invited international participants:

Prof. G. Socie MD, PhD

Service d'Hématologie Greffe. & Inserm U728
Hospital Saint-Louis, 1 Av. Vellefaux,
75010 Paris, France
e-mail: gerard.socie@sls.aphp.fr

Prof. Stephanie J. Lee, MD

Fred Hutchinson Cancer Research Center
1100 Fairview N
D5-290, Seattle, WA 98109
e-mail: sjlee@fhcrc.org

Prof. Steven Z. Pavletic, MD

Head of GVHD and Autoimmunity Unit
Experimental Transplantation and Immunology Branch
Center of Cancer Research
National Cancer Institute
10 Center Drive, CRC, Room 4-3130
Bethesda, MD 20892-1203
e-mail: pavletis@mail.nih.gov

Prof. Mohamad Mohty MD PhD

CHU de Nantes, Hématologie Clinique
Universite Nantes
Place A Ricordea
44093 Nantes Cedex, France
e-mail mohamad.mohty@univ-nantes.fr

Conference Venue

Hörsaal A 2
University Hospital Regensburg
Franz-Josef-Strauss-Allee 11
93053 Regensburg, Germany

General tourist and hotel information

Tourist-Information Altes Rathaus
Rathausplatz 4
93047 Regensburg
Germany
Tel.: +49-(0)941/507-4410
Tel.: +49-(0)941/507-4411
<http://www.tourismus.regensburg.de/tourismus/de/medienportal/1160>

Local Contact

PD Dr. Daniel Wolff
Dept. of Hematology and Oncology
University Hospital Regensburg
Franz-Josef-Strauß-Allee 11
93053 Regensburg

Tel.: +49- (0)941/944-5531
Fax: +49- (0)941/944-5543
Email: daniel.wolff@klinik.uni-regensburg.de

Registration Form

Please mail or fax to:
Susanna Blüml
Dept. of Hematology and Oncology
University of Regensburg
F.J. Strauss Allee 11, 93053 Regensburg, Germany
Phone: -49-941-944-5542
Fax: -49-941-944-5543
e-mail: Susanna.Blueml@klinik.uni-regensburg.de

Consensus Conference on Clinical Practice in Chronic GVHD Regensburg

6. - 7. November 2009

- I want to participate at the consensus conference
- I will not be able to participate at the consensus conference
- I need support with hotel reservation
-

Address:

Name: _____

Institution: _____

Address: _____

e-mail: _____

Phone: _____ Fax: _____